Relmada Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RLMD and other ETFs, options, and stocks.

About RLMD

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. 

CEO
Sergio Traversa
CEOSergio Traversa
Employees
17
Employees17
Headquarters
Coral Gables, Florida
HeadquartersCoral Gables, Florida
Founded
2012
Founded2012
Employees
17
Employees17

RLMD Key Statistics

Market cap
453.94M
Market cap453.94M
Price-Earnings ratio
-3.52
Price-Earnings ratio-3.52
Dividend yield
Dividend yield
Average volume
5.21M
Average volume5.21M
High today
$6.35
High today$6.35
Low today
$5.95
Low today$5.95
Open price
$6.23
Open price$6.23
Volume
890.87K
Volume890.87K
52 Week high
$7.51
52 Week high$7.51
52 Week low
$0.243
52 Week low$0.243

Stock Snapshot

With a market cap of 453.94M, Relmada Therapeutics(RLMD) trades at $6.19. The stock has a price-to-earnings ratio of -3.52.

During the trading session on 2026-03-12, Relmada Therapeutics(RLMD) shares reached a daily high of $6.35 and a low of $5.95. At a current price of $6.19, the stock is +4.0% higher than the low and still -2.5% under the high.

Trading activity shows a volume of 890.87K, compared to an average daily volume of 5.21M.

The stock's 52-week range extends from a low of $0.24 to a high of $7.51.

The stock's 52-week range extends from a low of $0.24 to a high of $7.51.

RLMD News

TipRanks 3d
Why Is Relmada Therapeutics Stock Up Today?

Relmada Therapeutics (RLMD) stock surged on Monday after the clinical-stage biotechnology company announced two updates. The first one concerned its Phase 2 cli...

TipRanks 3d
Relmada Therapeutics Raises Capital, Highlights Promising NDV-01 Data

Relmada Therapeutics ( (RLMD) ) has provided an announcement. On March 9, 2026, Relmada Therapeutics agreed to raise approximately $160 million through a priva...

TipRanks 3d
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01

Relmada Therapeutics (RLMD) announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive blad...

People also own

Based on the portfolios of people who own RLMD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.